IMAGINAB
ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized for clinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics.
IMAGINAB
Social Links:
Industry:
Biotechnology Clinical Trials Health Care Health Diagnostics
Founded:
2007-01-01
Address:
Inglewood, California, United States
Country:
United States
Website Url:
http://www.imaginab.com
Total Employee:
11+
Status:
Active
Contact:
8883953370
Email Addresses:
[email protected]
Total Funding:
59.64 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Global Site Tag Nginx
Current Advisors List
Current Employees Featured
Founder
Investors List
Theravance Biopharma
Theravance Biopharma investment in Venture Round - ImaginAb
Cycad Group
Cycad Group investment in Venture Round - ImaginAb
Norgine Ventures
Norgine Ventures investment in Venture Round - ImaginAb
Adage Capital Management
Adage Capital Management investment in Venture Round - ImaginAb
James Pallotta
James Pallotta investment in Venture Round - ImaginAb
Adage Capital Management
Adage Capital Management investment in Venture Round - ImaginAb
Nextech Invest
Nextech Invest investment in Venture Round - ImaginAb
Cycad Group
Cycad Group investment in Venture Round - ImaginAb
James Pallotta
James Pallotta investment in Venture Round - ImaginAb
Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy investment in Venture Round - ImaginAb
Official Site Inspections
http://www.imaginab.com Semrush global rank: 4.78 M Semrush visits lastest month: 1.92 K
- Host name: 104.21.80.1
- IP address: 104.21.80.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ImaginAb"
Meet our team - ImaginAB
Building long-term relationships that add value to the organization by utilizing ImaginAb’s CD8 ImmunoPET technology; Helping to advance clinical IO development; Prior to joining ImaginAb, Suzanne worked in various roles …See details»
ImaginAb - Crunchbase Company Profile & Funding
Organization. ImaginAb . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... ImaginAb is a clinical stage, revenue-generating global …See details»
About ImaginAb - developers of CD8ImmunoPET imaging agent
ImaginAb is a pioneering biotech company, innovating for tomorrow with modern radiopharmaceutical advances. Guided by an established team of clinical experts and …See details»
ImaginAb - LinkedIn
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its ...See details»
ImaginAb Company Profile 2024: Valuation, Funding
ImaginAb General Information Description. Developer of engineered antibody fragments designed to be used for diagnostic imaging and radioimmunotherapy. The company's fragments are based on a clinical product pipeline that …See details»
ImaginAb Company Profile - Office Locations, Competitors ... - Craft
ImaginAb is a bio-imaging company, which focuses on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. The …See details»
ImaginAb - Contacts, Employees, Board Members, Advisors
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins. ... Solutions. Products. Resources. Pricing. …See details»
ImaginAb - LinkedIn
ImaginAb | 4,886 followers on LinkedIn. Be the lead diagnostic and treatment choice...helping patients live better and healthier lives. | ImaginAb is a clinical stage, revenue-generating global …See details»
ImaginAb - Funding, Financials, Valuation & Investors - Crunchbase
ImaginAb is funded by 10 investors. Theravance Biopharma and Cycad Group are the most recent investors. ImaginAb has a post-money valuation in the range of $100M to $500M as of …See details»
ImaginAb: Building a Legacy of Excellence in Radiopharmaceutical ...
Ian Wilson’s Imprint on ImaginAb’s Journey. ImaginAb’s foundational values are deeply rooted in a singular vision—to improve the diagnosis and treatment of patients. The mission is a …See details»
ImaginAb - VentureRadar
ImaginAb, Inc. is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb’s platform …See details»
A Transformational Year: ImaginAb expands Pipeline to include ...
Oct 4, 2022 ImaginAb is a clinical stage, revenue-generating biotech company, with offices in the United States and the United Kingdom. ImaginAb is focused on developing next …See details»
ImaginAb completes $12.8 million financing to accelerate growth …
Jun 3, 2021 ImaginAb is advancing a pipeline of Minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic …See details»
IMAGINAB, INC Career Opportunities
ImaginAb are world leaders in the development of immunoPET and our late-stage imaging agent is utilized in a rapidly increasing number of trials. Alongside ImaginAb sponsored studies, we …See details»
Development Approach & Pipeline - ImaginAB
ImaginAb exist to challenge, create and to transform. We align this vision through every aspect of our strategy from development to market authorization and feedback. Everything we do is …See details»
ImaginAb signs multi-party collaboration agreement with three
Los Angeles, October 14, 2019 - ImaginAb Inc., a leading clinical stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with …See details»
Clarity Pharmaceuticals and ImaginAb to collaborate on new …
Jul 21, 2020 Sydney, Australia and Los Angeles, California 21 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious …See details»
ImaginAb - CD8 ImmunoPET Imaging Agent for immuno …
May 18, 2023 ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development. IAB56 RPT agent is designed to target integrin …See details»
ImaginAb technology to transform immuno oncology patient care
Our scientific advances are accelerating the progress of cancer treatment paths… Every day, we strive to discover and develop pioneering ways to equip physicians with the in-depth data they …See details»